159 related articles for article (PubMed ID: 20879886)
21. Syk kinase as a treatment target for therapy in autoimmune diseases.
Kyttaris VC; Tsokos GC
Clin Immunol; 2007 Sep; 124(3):235-7. PubMed ID: 17662659
[TBL] [Abstract][Full Text] [Related]
22. Kinase inhibitors for the treatment of rheumatoid arthritis.
Yazici Y; Steiger B
Bull NYU Hosp Jt Dis; 2012; 70(3):204-7. PubMed ID: 23259630
[TBL] [Abstract][Full Text] [Related]
23. The Syk kinase as a therapeutic target in leukemia and lymphoma.
Efremov DG; Laurenti L
Expert Opin Investig Drugs; 2011 May; 20(5):623-36. PubMed ID: 21438742
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Friedberg JW; Sharman J; Sweetenham J; Johnston PB; Vose JM; Lacasce A; Schaefer-Cutillo J; De Vos S; Sinha R; Leonard JP; Cripe LD; Gregory SA; Sterba MP; Lowe AM; Levy R; Shipp MA
Blood; 2010 Apr; 115(13):2578-85. PubMed ID: 19965662
[TBL] [Abstract][Full Text] [Related]
25. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.
Pine PR; Chang B; Schoettler N; Banquerigo ML; Wang S; Lau A; Zhao F; Grossbard EB; Payan DG; Brahn E
Clin Immunol; 2007 Sep; 124(3):244-57. PubMed ID: 17537677
[TBL] [Abstract][Full Text] [Related]
26. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Bajpai M
IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
[TBL] [Abstract][Full Text] [Related]
27. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors.
Bonilla-Hernán MG; Miranda-Carús ME; Martin-Mola E
Rheumatology (Oxford); 2011 Sep; 50(9):1542-50. PubMed ID: 21622522
[TBL] [Abstract][Full Text] [Related]
28. Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinib.
Boström E; Öhrn F; Hanze E; Sandström M; Martin P; Wählby-Hamrén U
J Clin Pharmacol; 2014 Dec; 54(12):1337-46. PubMed ID: 24895144
[TBL] [Abstract][Full Text] [Related]
29. Kinase inhibitors: a new class of antirheumatic drugs.
Kyttaris VC
Drug Des Devel Ther; 2012; 6():245-50. PubMed ID: 23055694
[TBL] [Abstract][Full Text] [Related]
30. The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
Hilgendorf I; Eisele S; Remer I; Schmitz J; Zeschky K; Colberg C; Stachon P; Wolf D; Willecke F; Buchner M; Zirlik K; Ortiz-Rodriguez A; Lozhkin A; Hoppe N; von zur Muhlen C; zur Hausen A; Bode C; Zirlik A
Arterioscler Thromb Vasc Biol; 2011 Sep; 31(9):1991-9. PubMed ID: 21700926
[TBL] [Abstract][Full Text] [Related]
31. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.
Norman P
Expert Opin Ther Pat; 2014 May; 24(5):573-95. PubMed ID: 24555683
[TBL] [Abstract][Full Text] [Related]
32. Novel small-molecular therapeutics for rheumatoid arthritis.
Fleischmann R
Curr Opin Rheumatol; 2012 May; 24(3):335-41. PubMed ID: 22357358
[TBL] [Abstract][Full Text] [Related]
33. The 2010 patent landscape for spleen tyrosine kinase inhibitors.
Moretto AF; Dehnhardt C; Kaila N; Papaioannou N; Thorarensen A
Recent Pat Inflamm Allergy Drug Discov; 2012 May; 6(2):97-120. PubMed ID: 22292554
[TBL] [Abstract][Full Text] [Related]
34. Novel small molecule therapeutics in rheumatoid arthritis.
Kelly V; Genovese M
Rheumatology (Oxford); 2013 Jul; 52(7):1155-62. PubMed ID: 23297340
[TBL] [Abstract][Full Text] [Related]
35. Can treating the SYK cell cure leukemia?
Downing JR
Cancer Cell; 2009 Oct; 16(4):270-1. PubMed ID: 19800569
[TBL] [Abstract][Full Text] [Related]
36. Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis.
Bajpai M; Chopra P; Dastidar SG; Ray A
Expert Opin Investig Drugs; 2008 May; 17(5):641-59. PubMed ID: 18447591
[TBL] [Abstract][Full Text] [Related]
37. Atheroprotection through SYK inhibition fails in established disease when local macrophage proliferation dominates lesion progression.
Lindau A; Härdtner C; Hergeth SP; Blanz KD; Dufner B; Hoppe N; Anto-Michel N; Kornemann J; Zou J; Gerhardt LM; Heidt T; Willecke F; Geis S; Stachon P; Wolf D; Libby P; Swirski FK; Robbins CS; McPheat W; Hawley S; Braddock M; Gilsbach R; Hein L; von zur Mühlen C; Bode C; Zirlik A; Hilgendorf I
Basic Res Cardiol; 2016 Mar; 111(2):20. PubMed ID: 26891724
[TBL] [Abstract][Full Text] [Related]
38. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Riccaboni M; Bianchi I; Petrillo P
Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
[TBL] [Abstract][Full Text] [Related]
39. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk.
Podolanczuk A; Lazarus AH; Crow AR; Grossbard E; Bussel JB
Blood; 2009 Apr; 113(14):3154-60. PubMed ID: 19096013
[TBL] [Abstract][Full Text] [Related]
40. Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN.
McAdoo SP; Reynolds J; Bhangal G; Smith J; McDaid JP; Tanna A; Jackson WD; Masuda ES; Cook HT; Pusey CD; Tam FW
J Am Soc Nephrol; 2014 Oct; 25(10):2291-302. PubMed ID: 24700868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
